Eileen Mary Boyle

Eileen Mary Boyle

Auto-generated profile, based on publicly available information

Eileen Mary Boyle

Myeloma Research Program, NYU Langone, Perlmutter Cancer Center

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 November 2015 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
Brian WalkerBrian Walker
Brian Walker
EBEileen M. Boyle
Eileen M. Boyle
CWChristopher Paul Wardell
Christopher Paul Wardell
AMAlex Murison
Alex Murison
DBDil B. Begum
Dil B. Begum
GMGareth John Morgan
Gareth John Morgan
Purpose: At the molecular level, myeloma is characterized by copy number abnormalities and recurrent translocations into the immunoglobulin heavy chain locus. Novel methods, such as massively parallel sequencing, have begun to describe the pattern of tumor-acquired mutations, but their clinical relevance has yet to be established. Methods: We performed whole-exome sequencing for 463 patients who presented with myeloma and were enrolled onto the National Cancer Research Institute Myeloma XI trial, for whom complete molecular cytogenetic and clinical outcome data were available. Results: We identified 15 significantly mutated genes: IRF4, KRAS, NRAS, MAX, HIST1H1E, RB1, EGR1, TP53, TRAF3, FAM46C, DIS3, BRAF, LTB, CYLD, and FGFR3. The mutational spectrum is dominated by mutations in the RAS (43%) and nuclear factor-κB (17%) pathways, but although they are prognostically neutral, they could be targeted therapeutically. Mutations in CCND1 and DNA repair pathway alterations (TP53, ATM, ATR, and ZNFHX4 mutations) are associated with a negative impact on survival. In contrast, those in IRF4 and EGR1 are associated with a favorable overall survival. We combined these novel mutation risk factors with the recurrent molecular adverse features and international staging system to generate an international staging system mutation score that can identify a high-risk population of patients who experience relapse and die prematurely. Conclusion: We have refined our understanding of genetic events in myeloma and identified clinically relevant mutations that may be used to better stratify patients at presentation.

23 April 2015 in Nature Communications
Verified
Journal Article
Open access
PDF file
Brian WalkerBrian Walker
Brian Walker
CWChristopher Paul Wardell
Christopher Paul Wardell
AMAlex Murison
Alex Murison
EBEileen M. Boyle
Eileen M. Boyle
DBDil B. Begum
Dil B. Begum
GMGareth John Morgan
Gareth John Morgan
We have sequenced 463 presenting cases of myeloma entered into the UK Myeloma XI study using whole exome sequencing. Here we identify mutations induced as a consequence of misdirected AID in the partner oncogenes of IGH translocations, which are activating and associated with impaired clinical outcome. An APOBEC mutational signature is seen in 3.8% of cases and is linked to the translocation-mediated deregulation of MAF and MAFB, a known poor prognostic factor. Patients with this signature have an increased mutational load and a poor prognosis. Loss of MAF or MAFB expression results in decreased APOBEC3B and APOBEC4 expression, indicating a transcriptional control mechanism. Kataegis, a further mutational pattern associated with APOBEC deregulation, is seen at the sites of the MYC translocation. The APOBEC mutational signature seen in myeloma is, therefore, associated with poor prognosis primary and secondary translocations and the molecular mechanisms involved in generating them.

1 January 2012 in Injury
Verified
Journal Article
Closed access
BFBernard Floccard
Bernard Floccard
LRLucia Rugeri
Lucia Rugeri
AFAlexandre Faure
Alexandre Faure
MDMarc Saint Denis
Marc Saint Denis
EBEileen Mary Boyle
Eileen Mary Boyle
BABernard Allaouchiche
Bernard Allaouchiche

6 January 2020 in Neurology
Verified
Journal Article
Closed access
PDF file
CHCaroline Houillier
Caroline Houillier
CSCarole Soussain
Carole Soussain
HGHervé Ghesquières
Hervé Ghesquières
PSPierre Soubeyran
Pierre Soubeyran
OCOlivier Chinot
Olivier Chinot
EGEmmanuel Gyan
Emmanuel Gyan
Objective Real-life studies on patients with primary CNS lymphoma (PCNSL) are scarce. Our objective was to analyze, in a nationwide population-based study, the current medical practice in the management of PCNSL. Methods The French oculo-cerebral lymphoma network (LOC) database prospectively records all newly diagnosed PCNSL cases from 32 French centers. Data of patients diagnosed between 2011 and 2016 were retrospectively analyzed. Results We identified 1,002 immunocompetent patients (43% aged >70 years, median Karnofsky Performance Status [KPS] 60). First-line treatment was high-dose methotrexate-based chemotherapy in 92% of cases, with an increasing use of rituximab over time (66%). Patients 60 years of age, WBRT and HCT-ASCT consolidation were administered in only 9% and 2%, respectively. The complete response rate to initial chemotherapy was 50%. Median progression-free survival was 10.5 months. For relapse, second-line chemotherapy, HCT-ASCT, WBRT, and palliative care were offered to 55%, 17%, 10%, and 18% of patients, respectively. The median, 2-year, and 5-year overall survival was 25.3 months, 51%, and 38%, respectively (60 years: 15.4 months, 44%, and 28%). Age, KPS, sex, and response to induction CT were independent prognostic factors in multivariate analysis. Conclusions Our study confirms the increasing proportion of elderly within the PCNSL population and shows comparable outcome in this population-based study with those reported by clinical trials, reflecting a notable application of recent PCNSL advances in treatment.

6 June 2017 in Leukemia
Verified
Journal Article
Open access
PDF file
VSV Shah
V Shah
ASA L Sherborne
A L Sherborne
Brian WalkerBrian Walker
Brian Walker
DJD C Johnson
D C Johnson
EBE M Boyle
E M Boyle
MKM F Kaiser
M F Kaiser
Robust establishment of survival in multiple myeloma (MM) and its relationship to recurrent genetic aberrations is required as outcomes are variable despite apparent similar staging. We assayed copy number alterations (CNA) and translocations in 1036 patients from the NCRI Myeloma XI trial and linked these to overall survival (OS) and progression-free survival. Through a meta-anlysis of these data with data from MRC Myeloma IX trial, totalling 1905 newly diagnosed MM patients (NDMM), we confirm the association of t(4;14), t(14;16), t(14;20), del(17p) and gain(1q21) with poor prognosis with hazard ratios (HRs) for OS of 1.60 (P=4.77 × 10−7), 1.74 (P=0.0005), 1.90 (P=0.0089), 2.10 (P=8.86 × 10−14) and 1.68 (P=2.18 × 10−14), respectively. Patients with ‘double-hit’ defined by co-occurrence of at least two adverse lesions have an especially poor prognosis with HRs for OS of 2.67 (P=8.13 × 10−27) for all patients and 3.19 (P=1.23 × 10−18) for intensively treated patients. Using comprehensive CNA and translocation profiling in Myeloma XI we also demonstrate a strong association between t(4;14) and BIRC2/BIRC3 deletion (P=8.7 × 10−15), including homozygous deletion. Finally, we define distinct sub-groups of hyperdiploid MM, with either gain(1q21) and CCND2 overexpression (P<0.0001) or gain(11q25) and CCND1 overexpression (P<0.0001). Profiling multiple genetic lesions can identify MM patients likely to relapse early allowing stratification of treatment.

4 May 2017 in Blood
Verified
Journal Article
Closed access
PDF file
CHCharles Herbaux
Charles Herbaux
JGJordan Gauthier
Jordan Gauthier
PBPauline Brice
Pauline Brice
EDElodie Drumez
Elodie Drumez
LYLoic Ysebaert
Loic Ysebaert
FMFranck Morschhauser
Franck Morschhauser
Key Points: PD-1 blockade with nivolumab provides durable disease control after allo-HCT. PD-1 blockade with nivolumab after allo-HCT is associated with 30% acute GVHD.